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Background: Overexpression of CEACAM6 has been reported for a number of malignancies. However, the
mechanism of how CEACAM6 contributes to cancer formation and its role in head and neck squamous cell
carcinoma (HNSCC) remains unclear. Therefore, we examined the role of CEACAM6 in head and neck squamous
cell carcinoma (HNSCC).
Methods: CEACAM6 expression was examined in normal squamous epithelia as well as a number of patient
HNSCC samples and tumours derived from HNSCC cell lines injected into NOD/SCID mice. CEACAM6 expression
was manipulated in HNSCC cell lines by shRNA-mediated CEACAM6 knockdown or virally-delivered overexpression
of CEACAM6. The role of CEACAM6 in tumour growth and chemotherapeutic sensitivity was then assessed in vivo
and in vitro respectively.
Results: CEACAM6 expression was significantly increased in highly tumourigenic HNSCC cell lines when compared
to poorly tumourigenic HNSCC cell lines. Moreover, HNSCC patient tumours demonstrated focal expression of
CEACAM6. Functional investigation of CEACAM6, involving over-expression and knock down studies, demonstrated
that CEACAM6 over-expression could enhance tumour initiating activity and tumour growth via activation of AKT
and suppression of caspase-3 mediated cell death.
Conclusion: We report that CEACAM6 is focally overexpressed in a large fraction of human HNSCCs in situ. We also
show that over-expression of CEACAM6 increases tumour growth and tumour initiating activity by suppressing
PI3K/AKT-dependent apoptosis of HNSCC in a xenotransplant model of HNSCC. Finally, our studies indicate that foci
of CEACAM6 expressing cells are selectively ablated by treatment of xenotransplant tumours with pharmacological
inhibitors of PI3K/AKT in vivo.
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CEACAM6 is a member of the cacinoembryonic antigen
(CEA) family of immunoglobulin glycoprotein cell adhe-
sion molecules (CAM) comprising at least 12 CEACAM
members [1]. CEACAMs are a diverse group of proteins
which play major roles in cell-cell and cell-ECM adhe-
sion and have been implicated in the control of cell* Correspondence: nsaunders@uq.edu.au
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reproduction in any medium, provided the orproliferation, angiogenesis and tissue remodelling [1].
More recently, CEACAMs have also been implicated in
mediating tissue responses to pathogens [1]. CEACAM6
is expressed at low levels in normal epithelial, endothelial
and hematopoetic cells including granulocytes, T-cells
and NK cells [2-4]. In contrast, CEACAMs are up-
regulated in many epithelial malignancies including
pancreatic, colorectal and breast cancers [5,6]. The ex-
pression of CEACAM6 also correlates with the metastatic
potential of some epithelial malignancies, suggesting that
the altered expression of CEACAM6 may contribute to
tumour progression [7]. However, a definitive role foral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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proved. For example, CEACAM6 appears to affect the
release of cytochrome-c from the mitochondria in
response to cell detachment leading to the inhibition of
caspase activation and hence, suppression of caspase
induced apoptosis or anoikis in pancreatic cancer cells
[8,9]. These apoptotic-suppressive effects have been
shown to be AKT-dependent in pancreatic cancer cells
[9]. Moreover, transgenic mice which overexpress mem-
bers of the CEA family display colonic dysplasia [10]. In
contrast, CEACAM6 up-regulation is associated with an
increase in apoptosis in acute lymphoblastic leukaemia
(ALL), indicating that the apoptosis-modulating effects of
CEACAM6 may be tumour-type-specific [4].
A recent transcriptomic profiling study comparing
highly tumourigenic clonal variants of an established
head and neck cancer squamous cell carcinoma
(HNSCC) cell line with poorly tumourigenic clonal var-
iants, identified a strong association between CEACAM6
expression and tumourigenic potential [11]. Since an as-
sociation between HNSCC and CEACAM6 expression
has not been previously reported we now examine
whether the over-expression of CEACAM6 is also
present in human HNSCC samples.Materials and methods
Cell culture and patient tumours
All HNSCC cell lines were obtained from the ATCC and
cultured as per ATCC recommendations (Sydney, NSW,
Australia). Patient tumour samples were all confirmed as
invasive squamous cell carcinoma (SCC) by a staff Path-
ologist (Princess Alexandra Hospital). Overall we exam-
ined 4 tongue SCC, 3 lip SCC and normal mucosae
from all these patients. Normal human epidermal kerati-
nocytes (HEKs) were isolated and cultured from neo-
natal foreskin samples following circumcision as
described [12,13]. Patient consent and approval by the
Princess Alexandra Hospital Human Ethics Committee
was obtained for all samples collected.Reverse transcriptase and real-time PCR (rt PCR)
Total RNA was isolated from cell lines with the addition
of trizol (Invitrogen, Melbourne, VIC, Australia) as per
manufacturer’s instructions. Quantification and reverse
transcriptase reaction was performed as previously
described [12]. The rtPCR CEACAM6 forward primer 5’
GACAGTTCCATGTATACCCG 3’ and the reverse
primer 5’ACAGCATCCTTGTCCTCC 3’, were obtained
from Sigma-Aldrich (Sigma-Aldrich, Sydney, NSW,
Australia). The rtPCR reaction solutions were prepared
and performed as per manufacturer’s instructions (Pro-
mega, Sydney, NSW, Australia). RtPCR reactions were
performed as previously described [14].Western blot analysis
Total cellular protein was isolated using RIPA buffer and
quantified as previously described [15]. Up to 20μg of
protein was loaded onto a 10% SDS-PAGE, transferred
onto PVDF membrane and probed as previously
described [15]. A 1/1000 dilution of anti-CEACAM6
antibody (Abcam, Sapphire Bioscience, Sydney, NSW,
Australia), 1/1000 dilution of of anti-AKT or anti-
phospho S473AKT [13] and a 1/1500 dilution of the sec-
ondary anti-mouse Horse Radish Peroxidase (HRP) (GE
Healthcare, Sydney, NSW, Australia) antibody was used
to detect protein using chemiluminescence as per manu-
facturer’s instructions (Pierce, Rockford, IL, USA). West-
ern blots were stripped as per manufacturers instruction
(Thermo Scientific, Rockford, Il, USA) to re-probe with
a 1/1000 dilution of β actin antibody (Sigma-Aldrich)
and a 1:2000 dilution of the anti-Rabbit HRP (GE
Healthcare) secondary antibody.
Cell proliferation and death assays in vitro
Bromo-deoxy uridine (BrdU) incorporation was used to
estimate proliferation in vitro. For BrdU analysis, cells
were plated at 104 cells per well in a 96 well plate
(Sigma-Aldrich) 24 hours prior to incubation with BrdU.
BrdU incubation and detection was performed as per
manufacturer’s instructions (Roche, Sydney, NSW, Aus-
tralia). In experiments examining the cytotoxic effects of
the PI3K/AKT inhibitor, BGT226, cells were treated for
48 hours with varying doses of BGT226 following which
viability was determined using the Celltiter assay kit
(Promega Madison, WI, USA, G3580) as described [13].
To measure basal levels of apoptosis in vitro Annexin V
was added to a single cell suspension of Detroit 562
cells. The single cell suspension was isolated from the
Detroit 562 cell line as previously described [11]. The
cells were stained with Annexin V Cy 5.5 as per manu-
factures instructions (BD Bioscience, Sydney, NSW, Aus-
tralia) and analysed using FACSCanto Diva version 2.2
Software (BD Pharminogen, Sydney, NSW, Australia).
Generation of a stable knock down of CEACAM6 in the
Detroit 562 cell line
For the generation of knock downs of CEACAM6, 2
microRNA interference (miR RNAi) sequences for CEA-
CAM6 were made. The primers for the first miR RNAi
sequence named miR CEA was, 5’ CACTGCCAAGCT
CACTATTGAC 3’ for the top strand and bottom strand
was 5’ GTCAATAGTGAGTGGCAGTG 3’. The other
miR RNAi sequence for CEACAM6 was named miR
CEA Dux, with a top strand of 5’ CCGGACAGTTCC
ATGTATACC 3’ and bottom stand of 5’ GGTATAC
ATGGCTGTCCGG 3’ based on the shRNA sequence
described in Duxbury et al. [16]. The pLENTI 6.1 miR
RNAi sequences for miR CEA, miR CEA Dux and
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the Detroit 562 cell line as per manufacturer’s instruc-
tions (GATEWAY pLENTI cloning system, Invitrogen).
Generation of a stable over-expression of CEACAM6 in
the Detroit 562 cell line
The forward primer of 5 GGGGACAAGTTTGTACA
AAAAAGCAGGCTCACCATGGGAGACCATGGGACC
CCCCTCA3’ (attB1 site underlined) and reverse
primer of 5’ GGGGACCACTTTGTACAAGAAAGC
TGGGTGGGCTGCTATATCAGAGCCAC 3’ (attB2 site
underlined) were used to generate full length CEAC
AM6 sequence from human epidermal keratinocytes
(HEK) cDNA. The PCR conditions were as per manufac-
tures instructions for Hifi taq (Promega). The CEACAM6
sequence was cloned into pDONR 221 (Invitrogen) using
a BP reaction, then an LR reaction into pLV101G as per
manufactures instructions (Invitrogen). The pLV101-
Ceacam6 and pLV101 (control vector) Detroit 562 cell
were generated as previously described [14].
Tumour initiation and tumour collection
Tumour initiation studies, in vivo tumour treatment
with the PI3K/AKT inhibitor, BGT226, and tumour sec-
tioning were performed as previously described [11,13].
Immunohistochemistry
Immunohistochemistry performed as previously described
[11] using CEACAM6 (Biogenex, Australia), PCNA
(3.2 μg/ml, Sigma-Aldrich) and Cleaved caspase 3
(0.8 μg/ml, Promega) antibodies. Control antibodies were
Rabbit IgG (DAKO, Copenhagen, Denmark) and Mouse
IgG (DAKO). The percentage of positive cells (PCNA
and Cleaved Caspase 3) was quantified as the number
of positive cells per 40x magnified field of view from
a minimum of 5 to 10 randomly selected fields using
NIS-Elements BR3.1 image software (Nikon, Coherent
Scientific, Adelaide, SA, Australia).
Statistical analysis
Student’s t test was used to assess the significance of differ-
ences between means of the different sample conditions.
Results
CEACAM6 expression in HNSCC
We have previously reported that CEACAM6 is over-
expressed in a highly tumourigenic clonal variant of
the Detroit 562 HNSCC cell line [10]. We now
examine the prevalence of CEACAM6 expression in a
suite of HNSCC cell lines and human HNSCC samples
(Figure 1). CEACAM6 mRNA expression was 177 fold
over-expressed in the Detroit 562 cell line and 12 fold
over-expressed in Cal27 cell line when compared to nor-
mal human epidermal keratinocytes (HEKs, Figure 1A).We have previously reported that the Detroit 562, Cal27
and FaDu cell lines are able to form tumours in a xeno-
transplant model with ≤1 × 104 cells whilst the SCC25,
SCC9 and SCC15 cell lines are poorly tumourigenic, re-
quiring ≥3 × 104 cells to initiate a tumour [11]. Grouping
the HNSCC cell lines based on tumourigenesity (highly
tumourigenic ≤ 104 cells or poorly tumourigenic ≥
3 × 104 cells), we were able to show an association be-
tween tumourigenesity and CEACAM6 expression
(Figure 1B compare High TI vs Low TI). Highly tumouri-
genic cells had higher expression of CEACAM6 whilst
poorly tumourigenic cells had relatively low levels of
CEACAM6 expression (Figure 1B). However, this associ-
ation is not absolute when correlating total CEACAM6
expression and tumourigenic activity. A more detailed
examination of CEACAM6 expression levels by immuno-
histochemistry, in patient SCC samples (Figure 1D)
revealed that CEACAM6 was present in 6 out of 7 patient
samples (Figure 1D). All tumour samples were invasive
SCC of the tongue (n = 4) or lip (n = 3). Most signifi-
cantly, we found the expression of CEACAM6 to be fo-
cally overexpressed in the patient tumours which was
consistent with the focal expression of CEACAM6
observed in tumours derived from the Detroit 562 paren-
tal cell line (Figure 1C) [11]. Image analysis revealed that,
on average across all the tumour samples, 28% +/− 12%
of the total tumour area was positive for CEACAM6 ex-
pression. However, it should be noted that the percentage
area positive for CEACAM6 varied from approximately
60% down to 0% between individual tumours. Moreover,
CEACAM6 positivity was often associated with keratin
pearls within the tumour samples (Figure 1D). Analysis of
normal human oral mucosa indicated that CEACAM6
expression is present on the plasma membranes within
the suprabasal differentiated layers of the mucosa
(Figure 1C). The focal expression of CEACAM6 in
tumours derived from the Detroit 562 cell line was con-
sistent with our earlier study reporting that clonal variants
existed within the parental Detroit 562 cell line that could
be discriminated based on variant-specific transcriptomic
signatures [11]. These findings highlight 2 important
observations. Firstly, the majority of HNSCC have foci of
CEACAM6 overexpression. Secondly, examining global
expression of CEACAM6, at a tissue level, is not a good
indicator of the presence or abundance of CEACAM6+ve
foci/clonal variants within cell cultures or tumours. The
concept of intratumoural heterogeneity has recently been
validated by single cell sequencing techniques in patient
tumours and has significant implications for tumour pro-
gression and drug resistance [17].
The role of CEACAM6 in HNSCC tumourigenesity
CEACAM6 is i) overexpressed focally in SCC, ii) overex-
pressed in SCC cell lines and iii) CEACAM6 expression
Figure 1 CEACAM6 expression in HNSCC cell lines and patient tumours. A) RtPCR analysis of CEACAM6 mRNA expression in subconfluent
cultures ofHNSCC cell lines and normal HEKs (n = 4). High tumour initiating (TI) activity refers to cell lines that require less than 104 cells to form a
tumour and low TI activity refers to cell lines that require greater than 3x104 cells to form a tumour in NOD/SCID mice. B) Comparison of
CEACAM6 mRNA expression between high TI and Low TI cell lines (n = 4). C) CEACAM6 expression in a xenotransplanted tumour derived from
the Detroit 562 cell line and the staining pattern for CEACAM6 in a normal oral mucosal sample. D) CEACAM6 expression in HNSCC patient
tumours. Arrows point to areas of focal expression of CEACAM6. All images taken at 20x magnification (boxed inserts are IgG control sections).
All data presented as mean +/− sem. * refers to P ≤ 0.05.
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fore, we used the Detroit 562 cell line to examine the
contribution of CEACAM6 to tumour initiating activity
and/or tumour growth. CEACAM6 overexpression was
achieved using a lenti-viral over-expression vector
(Figure 2A, B). To determine whether the over-
expression of CEACAM6 was able to modulate prolif-
eration and cell death, BrdU and Annexin V assays were
performed in vitro (Figure 2C, D). The BrdU assay for
proliferation indicated a 5-fold increase in CEACAM6expression was associated with a 50% reduction in pro-
liferation in the Detroit 562 cell line in vitro (Figure 2C).
In contrast, CEACAM6 overexpression significantly
enhanced Annexin V positivity in vitro (Figure 2D).
Next, we examined the effect of overexpressing CEA-
CAM6 in Detroit 562 cells on tumour initiation and
growth in vivo in our xenotransplant model. CEACAM6
overexpressing SCC cells (Detroit 562 pLV101-CEA-
CAM6) were able to initiate tumours with 1 × 104 cells
whereas vector-infected control cells (Detroit 562
Figure 2 Impact of CEACAM6 over-expression on proliferation and apoptosis in the Detroit 562 cell line. A) Rt-PCR analysis of CEACAM6
mRNA expression in pLV101 control and pLV101 CEA transduced Detroit 562 cells. B) CEACAM6 protein expression in control and pLV101 CEA
transduced Detroit 562 cells. β-actin is provided as a reference for loading equivalence. C) BrdU incorporation in control (PLV101) and pLV101
CEA transduced Detroit 562 cells (n = 6). BrdU is reported as Absorbance Units/well (A450nm-A560nm). D) Percentage of total cells that express
Annexin V in control (PLV101) and pLV101 CEA transduced Detroit 562 cells. Data presented as mean +/− sem of at least 3 independent
experiments performed in triplicate. * P ≤ 0.05.
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(Figure 3A). Immunohistochemical staining confirmed
that overexpression of CEACAM6 persisted in vivo to
the termination of the study (Figure 3B). Finally, we
found that overexpression of CEACAM6 resulted in a
modest increase in the expression of the proliferation
marker, PCNA, when compared to control tumours
(Figure 3C). Significantly, overexpression of CEACAM6
in Detroit 562 cells was accompanied by a profound and
significant decrease in the apoptotic index of tumour
cells in vivo compared to control tumours (Figure 3D).
These data indicate the enhanced tumour growth
observed in the CEACAM6 over-expressing cells was
predominantly attributable to a decrease in caspase
3-dependent cell death in vivo. These effects were not
observed in vitro and suggest that CEACAM6-mediated
alterations in tumour proliferation and apoptosis are
regulated by factors specific for the microenvironment
in which the tumours reside in vivo. Differences in
in vitro and in vivo apoptotic responses are not unex-
pected. We have previously reported that agents such as
histone deacetylase inhibitors exhibit substantial cyto-
toxic effects on SCC cells in vitro yet fail to induce cyto-
toxicity against SCC cells in xenotransplant models or
human subjects [13,18]. Moreover, a recent study
reported that stromal elements are able to modify
tumour cell sensitivity to cytotoxic drugs [19].Next, we investigated whether reducing CEACAM6
expression would also be able to modulate tumour initi-
ation and growth in the Detroit 562 cell line. Efficiency
of knock down of CEACAM6 was achieved using 2 miR
RNAi sequences, miR CEA and miR CEA Dux, and was
measured by rt PCR (Figure 4A). CEA Dux sequence
had the greatest knock down of the 2 sequences, with
96.98% knock down at the mRNA level. Using the CEA
Dux sequence, the knock down of CEACAM6 was con-
firmed at the protein level (Figure 4B). BrdU and
Annexin V assay analysis indicated that knock down of
CEACAM6 in the Detroit 562 cells had no significant
effect on the proliferative potential or basal levels of cell
death compared to control cells (Figure 4C and D). This
would suggest that the modest effects of overexpression
of CEACAM6 on proliferation and apoptosis observed
in an in vitro setting may be an artefact of overexpres-
sion. Next, we examined the ability of CEACAM6 Dux
(miR CEA Dux) transduced or control-transduced (miR
Control) cells to establish tumours in a xenotransplant
model (Figure 5A, B). CEACAM6 knockdown cells took
longer to establish and grow than control cells
(Figure 5A, B). Immunohistochemistry confirmed that
knock down of Ceacam6 persisted to the termination of
the study in xenotransplanted tumours (Figure 5C).
These data indicate that CEACAM6 expression was
reduced, but not completely ablated, in the CEACAM6-
Figure 3 Effect of CEACAM6 overexpression on tumour initiation. A) Varying numbers of control (PLV101 control) or CEACAM6
overexpressing (PLV101 CEA) Detroit cells were assayed for their ability to initiate tumours in NOD/SCID mice. Mice (6/group) were monitored
over a 12 week period and the incidence of tumours and the time till tumours were palpable is recorded. B) CEACAM6, PCNA and cleaved
Caspase 3 expression was determined immunohistochemically at 4x and 20x magnification in xenotransplant tumours derived from pLV101
control and pLV101 CEACAM6 over-expressing cells (insets are IgG control sections). C, D) PCNA positivity in the CEACAM6 over-expressing and
control tumours was estimated as the number of positive cells per 100 cells in a field of view by NIS-Elements BR3.1 imaging software.
Quantification of cleaved caspase 3 expression (D) was estimated as number of positive cells per field of view by NIS-Elements BR3.1 imaging
software. All data expressed as mean +/− sem. * P ≤ 0.05.
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tumours. Combined, the overexpression and knockdown
studies show that CEACAM6 can enhance the tumouro-
genesity of HNSCC cells. Moreover, we show that CEA-
CAM6 overexpression enhances tumourogenesity by
inhibiting apoptosis.
We have shown that CEACAM6 can increase tumour
initiating activity and inhibit apoptosis (Figures 3 and 4).
Thus, we were interested in whether the antiapoptotic
effects of CEACAM6 could extend to the suppression of
cytotoxic activity of a PI3K/AKT/mTOR inhibitor,
BGT226 [13]. Human SCC frequently harbor defects in
survival pathways such as the PTEN/PI3K/AKT/mTOR
pathway which can attenuate responses to chemother-
apeutics [see 15]. Moreover, it has been previously
reported that CEACAM6 can inhibit cytotoxicity inducedby a conventional chemotherapeutic, gemcitabine, in pan-
creatic cancer cells [9]. Anticancer treatments are increas-
ingly relying on the use of targeted therapies [17] and we
have previously shown that targeting the PI3K/AKT/
mTOR pathways in HNSCC shows considerable antican-
cer activity in xenotransplant models of HNSCC [13]. We
compared the sensitivity of Detroit 562 cells (PLV101)
(Figure 6) to the PI3K/AKT inhibitor, BGT226, with the
sensitivity of Detroit 562 cells in which CEACAM6 is
overexpressed (PLV101-CEA) (6A) or knocked down by
stable expression of an shRNA (mir CEA-Dux)
(Figure 6A). Figure 6 shows that inhibition of CEACAM6
enhances sensitivity of SCC cells to BGT226 (Ec50 shifts
from 230 nM in PLV101 to 14.3 nM in mir CEA-Dux
cells). Overexpression of CEACAM6 reduces the sensitiv-
ity (Ec50 = 138 nM in PLV101-CEA) and maximal
Figure 4 Knock down of CEACAM6 in the Detroit 562 cell line. A) The mRNA expression of CEACAM6 in control miR RNAi and 2 miR RNAi
knock down sequences (miR CEA and miR CEA Dux) was quantified by rtPCR analysis. B) The knock down of CEACAM6 using miR CEA Dux was
confirmed at the protein level using western blot analysis. C) BrdU incorporation in control (miR Control) and knock down detroit cells (miR CEA
Dux) is shown (n = 6). BrdU is reported as Absorbance Units/well (A450nm-A560nm). D) Percentage of total cells that express Annexin V positivity in
control (miR Control) and knockdown Detroit cells (miR CEA Dux) is shown. Data presented as mean +/− sem of at least 3 independent
experiments performed in triplicate. * P ≤ 0.05.
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in PLV101 and 50% in PLV101-CEA). Moreover, we show
that overexpression of CEACAM6 causes an induction of
AKT whilst knockdown of CEACAM6 causes a reduction
in total and phospho-S473 AKT (Figure 6B). These data
indicate that CEACAM6 is a modulator of the constitu-
tive PI3K/AKT survival pathway in SCC cells and is able
to modulate the cytotoxic response to pharmacological
inhibitors of the PI3K/AKT pathway. Finally, we had pre-
viously reported that SCC cells when grown, in a xeno-
transplant model, display initial transient sensitivity to
BGT226 followed by the expansion of BGT226-resistant
cells [13]. We now report that 4 weeks of daily treatment
with BGT226 of mice bearing tumours derived from De-
troit 562 cells selectively ablates CEACAM6-positive foci
in the tumours (Figure 6B).
Discussion
In this study we report, for the first time, on the role of
CEACAM6 in HNSCC. Previous work with keratino-
cytes and keratinocyte-derived SCC cells has shown that
CEACAM6 is selectively expressed in differentiated ker-
atinocytes [2] and is highly expressed in a tumourigenic
clonal variant of the Detroit 562 HNSCC cell line [10].In addition, other workers have reported that i) CEA-
CAM6 overexpression occurs in variety of epithelial
malignancies [5-7], ii) that CEACAM6 overexpression is
associated with increased metastases, proliferation and
the suppression of annoikis [7-9], iii) that CEACAM6
overexpression induces a src-dependent increase in AKT
activity that suppresses gemcitabine sensitivity in pan-
creatic cancer cells [9] and finally, iv) a transgenic model
of CEA-overexpression suggests CEACAM6 overexpres-
sion can contribute to the development of colonic dys-
plasia [10]. We now extend these findings and report
that CEACAM6 is focally overexpressed in a large frac-
tion of human HNSCCs in situ. The heterogeneous pat-
tern of CEACAM6 overexpression is also evident in
established HNSCC cell lines in vitro and in vivo. More-
over, we show that over-expression of CEACAM6
increases tumour growth and tumour initiating activity
by suppressing PI3K/AKT-dependent apoptosis of
HNSCC in a xenotransplant model of HNSCC. Finally,
we show that foci of CEACAM6 expressing cells are se-
lectively ablated by treatment of xenotransplant tumours
with pharmacological inhibitors of PI3K/AKT in vivo.
A novel finding in the present study is the observation
that CEACAM6 is focally overexpressed in the majority
Figure 5 Tumour initiation studies of CEACAM6 knock down. A, B). Tumour initiation study was performed with the CEACAM6 knock down
(miR CEA Dux) and control (miR Control) cells as described in Figure 3 (6 mice/group). C) Expression of CEACAM6 in the CEACAM6 knock down
and control xenotransplant tumours at 4x and 20x magnification (inserts are of IgG control sections).
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was small it highlights an important issue that has im-
portant biological and clinical implications. Specifically,
intratumoural heterogeneity is a major contributor to
the emergence of drug resistance and tumour recurrence
[17]. Consistent with this, our data suggest that focal
overexpression of CEACAM6 is indicative of sensitivity
of human HNSCC to selective cytotoxic drugs. In
this regard two observations relating to CEACAM6 are
relevant. Firstly, knockdown or overexpression of CEA-
CAM6 resulted in a decrease and increase in tumouri-
genic activity in SCC cells in vivo respectively. Secondly,
CEACAM6 has been shown to modulate the cytotoxic
effects of conventional chemotherapeutics such as gem-
citabine in pancreatic cancer cell lines [9] and in the
present study we showed that CEACAM6 could mediate
sensitivity to new targeted agents such as the PI3K in-
hibitor, BGT226. It is noteworthy that the modulation of
gemcitabine sensitivity is also mediated via a src and
PI3K/AKT-dependent pathway [9]. These data indicate
that whilst CEACAM6 may invoke pro-survival
responses in cancer cells by activating the PI3K/AKT
pathway this same pathway could be selectively targeted
by specific cytotoxic drugs. Thus, the presence of CEA-
CAM6+ve foci would be predicted to bestow selective
sensitivity against certain chemotherapeutic treatments
(eg: gemcitabine or PI3K inhibitors). Proof of principle
for this hypothesis is shown by the reduction in phospho-
S437 AKT induced by knockdown of CEACAM6 and theloss of CEACAM6+ve foci in tumours treated with cyto-
toxic doses of PI3K inhibitors. Thus, CEACAM6 could be
used to predict PI3K inhibitor sensitivity. Moreover, the
observation that CEACAM6 expression correlates with
metastatic potential [8,20-22] would suggest that, in
chemotherapy-naive tumours, the presence of CEACAM6
+ve foci could serve as a prognostic marker of poor out-
come and in this instance targeting CEACAM6/PI3K/AKT
pathways could be exploited therapeutically. Supporting
this, is a recent study, by Blumenthal et al. [20], demon-
strating that the addition of antibodies that inhibited the
binding of CEACAM6+ve breast cancer cells to endothelial
cells reduced tumour cell invasion [20]. Finally, intratu-
moural heterogeneity can arise through a number of
mechanisms such as the evolution of variant cells from a
common clonal precursor, micro-environmental influ-
ences, stochastic processes or tissue/cell plasticity [17]. The
present study suggests that the focal pattern of CEACAM6
expression, in tumours, is derived from a specific clonal
progenitor within the tumour rather than being transiently
induced by the local environment. This is based on the ob-
servation that CEACAM6+ve and –ve cells persist in long
term tissue culture models, consistent with an heritable
mechanism (eg: genetic or epigenetic).
Whilst CEACAM6 clearly has the capacity to contrib-
ute to drug resistance and tumour recurrence it is clear
that other factors also contribute to drug resistance and
tumour recurrence. This is supported by our observation
that targeted inhibition of the CEACAM6/PI3K/AKT
Figure 6 CEACAM6 expression in tumours treated with a PI3K/AKT inhibitor. A) Subconfluent cultures of Detroit 562 cells transduced with
vector (pLV101), knockdown construct (mir CEA Dux) or overexpression vector (pLV101-CEA) were exposed to varying concentrations of BGT226
for 48 hours after which viability was assessed. Data presented as mean± sem from 2 experiments performed in triplicate. B) Protein was
harvested from untreated cells used in (A) and CEACAM6, AKT or phospho-S437 AKT protein expression estimated by western blot. β-actin
expression is presented to confirm loading equivalence. C) 106 cells used in (A) were injected into NOD/SCID mice and when tumours reached
0.4 cm3 the mice were treated with daily doses of vehicle or BGT226 as described elsewhere [13]. Mice were sacrificed when tumours reached
1 cm3 and tumours removed, fixed and 5 μm sections stained for CEACAM6 expression. Note mice treated with BGT226 displayed significant
reductions in tumour growth and time to sacrifice was significantly extended in these mice [13]. An IgG negative control is shown on the left.
Six mice per group were used and a representative section from one mouse is shown. 20X magnification.
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HNSCC cells. Similarly, we have identified clonal var-
iants of HNSCC cells that express very low levels of
CEACAM6 yet still retain tumourigenic potential [11].
Moreover, we show that the knockdown of CEACAM6
results in a decrease, but not an ablation, of tumour ini-
tiating activity or tumour growth. Thus, CEACAM6
likely represents one factor, of many, that can modulate
tumour growth and tumour initiating activity. This is
entirely consistent with the emerging importance of intra-
tumoural heterogeneity [17]. We previously reported that
HNSCC display intratumoural heterogeneity that was
reflected in histomorphologically and transcriptomically
distinct clonal variants [11,14]. We showed that clonal
variants of HNSCC cells could persist in vitro in estab-
lished cell lines and displayed significant differences in
tumour initiating activity and drug resistance [11,13,14].
Several groups have now definitively shown, by single cell
sequencing, that tumours comprise multiple genetically
distinct clonal populations [23-27]. Emerging, clinical
and molecular data unequivocally show that the presence
of intratumoural heterogeneity, exemplified by focal
CEACAM6 overexpression in HNSCC cells, is a major
contributor to tumour drug responses and patient out-
comes [17].
Earlier work by Duxbury [28], suggests that the major
contribution of CEACAM6 to tumour growth andtumour initiating activity is mediated via suppression of
anoikis. Anoikis is a form of apoptosis induced by loss of
cell-cell/EMC contact. Thus, anoikis may be more rele-
vant to a 3 dimensional tumour environment rather
than an in vitro cell monolayer system. [29]. Supporting
this, we found that the in vivo effects of CEACAM6
over-expression/knockdown were not reflected by the
in vitro effects of CEACAM6. For instance, CEACAM6
over-expression/knockdown had modest and inconsist-
ent effects on apoptotic rates in vitro. However, over-
expression of CEACAM6 significantly reduced caspase-3
dependent apoptosis of HNSCC cells in a xenotransplant
model. Anti-apoptotic activity is commonly viewed as
tumour promoting and hence the anti-apoptotic activity
of CEACAM6 would suggest it has tumour promoting
(oncogenic) activity [30]. CEACAM6-mediated inhib-
ition of apoptosis in vivo therefore contributes in part,
or wholly, to the ability of HNSCC cells to initiate a
tumour in a xenotransplant model of HNSCC. In
addition, CEACAM6 over-expression also contributes in
part, or wholly, to the increased tumour growth in a
xenotransplant model of HNSCC. Based on these find-
ings, it is reasonable to speculate that focal patches of
CEACAM6 expressing cells within HNSCC may reflect
the presence of a subpopulation of cells with a greater
potential for recurrence/metastasis than CEACAM6-ve
subpopulations of HNSCC cells.
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In conclusion, our study shows that CEACAM6 is fo-
cally overexpressed in a large fraction of human
HNSCCs in situ and contributes to tumour growth and
tumour initiating activity. The effect of CEACAM6 on
tumour growth and initiation is mediated via suppres-
sion of PI3K/AKT-dependent apoptosis of HNSCC in a
xenotransplant model of HNSCC. Finally, our studies
show that CEACAM6+ve tumours, or tumour foci, are
selectively sensitive to treatment with pharmacological
inhibitors of PI3K/AKT in vivo.
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